NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Many companies have developed or are developing machines to handle such other cell types - but not adherent cells.

Well, maybe in Linda speak.

Back in the real world we see one of the industry leaders, CliniMACS already has a commercial DC production capability. Would not surprise me at all if others did as well. (Quantum for example).

To meet the increasing regulatory requirements for cell-based therapeutics, we integrated all manufacturing steps in a closed system operated by an automated cell processing instrument, the CliniMACS Prodigy® (fig. 1). Here we show the detailed phenotypic and functional characterization of Mo-DCs from several independent production batches derived from apheresis samples obtained from healthy donors.

In the mean time NWBO is just several months away from having the first actual unit they can start testing.

And the CliniMACS website page advertising the applictaion.